PDB24 COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
May 1, 2019, 00:00 AM
10.1016/j.jval.2019.04.574
https://www.valueinhealthjournal.com/article/S1098-3015(19)30766-1/fulltext
Section Title :
Section Order :
10202
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30766-1&doi=10.1016/j.jval.2019.04.574